Quick Answer
Regen BioPharma Inc reported Diluted EPS of $0.05 per share (loss) for fiscal year 2025.
Regen BioPharma Inc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.05 | +68.8% |
| 2024 | -$0.16 | -155.2% |
| 2023 | $0.29 | -59.2% |
| 2022 | $0.71 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.01 | +92.3% | +0.0% |
| June 30, 2025 | -$0.01 | +66.7% | — |
| March 31, 2025 | $0.00 | +100.0% | +100.0% |
| December 31, 2024 | -$0.13 | -225.0% | -333.3% |
| June 30, 2024 | -$0.03 | +0.0% | +0.0% |
| March 31, 2024 | -$0.03 | — | +25.0% |
| December 31, 2023 | -$0.04 | -108.9% | -33.3% |
| June 30, 2023 | -$0.03 | — | -106.7% |
- Regen BioPharma Inc showed an increase of +68.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Regen BioPharma Inc’s diluted eps has declined by 107.0% (from $0.71 per share to $0.05 per share (loss)).
- The most recent figure is from Regen BioPharma Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: